[
    "{\"step_by_step_thinking\": \"Based on the provided documents, there is evidence to suggest that Selumetinib is effective for low-grade glioma. Document [1] reports the results of a phase 2 trial in pediatric patients with low-grade glioma, where Selumetinib showed activity and led to sustained partial responses. Document [3] also mentions a phase 2 trial of Selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma, which resulted in partial responses and stable disease. Additionally, Document [8] states that Selumetinib has shown promising activity in pediatric low-grade glioma. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]